Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTX3034 in Solid Tumors With KRASG12D Mutation
NCT06227377Phase 1Recruiting
- Sponsor
- Quanta Therapeutics
- Start
- Feb 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of QTX3034 in solid tumor (4 arms), sponsored by Quanta Therapeutics. Primary endpoints: Dose Limiting Toxicities at 21 days and Treatment-emergent Adverse Events at 2 years. Started Feb 2024; status: recruiting.
02
Drugs
QTX3034
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06227377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227377.